Internal Medicine News - Sibutramine metaanalysis
Friday, December 26th, 2008 Sibutramine use was significantly associated with weight loss and appears to improve glycemic control and lipid profile in type 2 diabetics, reported Roberto Vettor, M.D., of the University of Padova, Italy, and his colleagues.
In a metaanalysis of eight placebo-controlled, double-blind trials, 552 obese patients with type 2 diabetes were randomized to sibutramine treatment, and 541 were randomiz…
